The tunneling nanotube (TNT) is a novel type of cellto-cell communicator, 50-2 nm in diameter, F-actin containing structure connecting two or more cells. TNTs have been observed in a variety of cells to transport different components such as mitochondria, cell membrane components, multi-resistance genes and pathogens (like retroviruses and bacteria). The exact molecular mechanisms behind TNT formation are still unclear. HTLV-1 hijacks TNT-like structures for its transmission through the viral encoded p8 protein that augments the number and length of these TNT-like structures to favor virus transmission among T-cells. We have previously investigated TNTs in the heterogeneous and aggressive blood cancer, acute myeloid leukemia (AML), and found that the chemotherapeutic cytarabine (AraC) down-regulates TNT production in AML cells. Thus we wish to apply this knowledge to investigate whether AraC may exert a similar effect in T-cells and monocytes resulting in decreased HTLV-1 transmission. Furthermore we will measure the drug's effect on the transfer of the p8 protein to uninfected cells such as primary PBMCs, Jurkat T cells and THP-1 cells. We have generated Jurkat T and THP-1 cells stably expressing mem-GFP and mem-Cherry proteins for livecell visualization of TNT and TNT-like structures by fluorescence microscopy. The results will be presented. Cite this article as: Omsland et al.: The effect of chemotherapeutics on cell-to-cell transport of HTLV-1 and the p8 protein through membrane nanotubes. Retrovirology 2015 12(Suppl 1):P8.
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